Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2790)
All Articles published online
|
Nov 28, 2012 (publication date) through Jun 14, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Arkenau HT, Saggese M, Lemech C. Advanced gastric cancer: Is there enough evidence to call second-line therapy standard? World J Gastroenterol 2012; 18(44): 6376-6378 [PMID: 23197882 DOI: 10.3748/wjg.v18.i44.6376] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v18/i44/6376.htm |
| Number | Citing Articles |
| 1 |
Gebra Cuyun Carter, Denise T. King, Lisa M. Hess, Stephen A. Mitchell, Kaisa-Leena Taipale, Urpo Kiiskinen, Narayan Rajan, Diego Novick, Astra M. Liepa. Health state utility values associated with advanced gastric, oesophageal, or gastro-oesophageal junction adenocarcinoma: a systematic review. Journal of Medical Economics 2015; 18(11): 954 doi: 10.3111/13696998.2015.1066380
|
| 2 |
Ya-Kun Jiang, Wei Li, Ying-Yang Qiu, Meng Yue. Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer. World Journal of Gastrointestinal Oncology 2024; 16(6): 2318-2334 doi: 10.4251/wjgo.v16.i6.2318
Abstract(14) |
Core Tip(12) |
Full Article(HTML)(41)
|
Full Article with Cover (PDF)-10337K(3)
|
Audio-441K(0)
|
Peer-Review Report-231K(2)
|
Answering Reviewers-70K(2)
|
Supplementary Material-8723K(4)
|
Full Article (PDF)-10027K(2)
|
Full Article (XML)-321K(2)
|
Times Cited (0)
|
Total Visits (107)
|
Open
|
| 3 |
Carles Pericay, Fernando Rivera, Carlos Gomez‐Martin, Inmaculada Nuñez, Alejo Cassinello, Esteban Rodrigo Imedio. Positioning of second‐line treatment for advanced gastric and gastroesophageal junction adenocarcinoma. Cancer Medicine 2016; 5(12): 3464 doi: 10.1002/cam4.941
|